Related Experiment Video
Updated: Oct 14, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology
1Department of Immunology, Medical University of Warsaw, Warsaw, Poland.
Introduction:
Therapeutic cancer vaccines have been recognized as a promising treatment option in clinical oncology for nearly three decades. However, despite many efforts, only one cancer vaccine - sipuleucel-T, activating the anti-PAP (prostatic acid phosphatase) immune response, has obtained Food and Drug Administration (FDA) approval.
Material And Methods:
This review describes the most advanced research on the use of therapeutic cancer vaccines in the treatment of prostate cancer.
Results:
In addition to sipuleucel-T, which was approved in urologic oncology in 2010, four cancer vaccines were and have been tested in phase III clinical trials in patients with metastatic castration resistant prostate cancer (mCRPC): GVAX (prostate cancer variant) containing irradiated prostate cancer cell, PPV peptide vaccine, PCVAC/PCa dendritic cell-based vaccine and PROSTVAC anti PSA (prostate-specific antigen) vaccine. This review compares the most promising and best-studied cancer vaccines: sipuleucel-T and PROSTVAC. Currently, both vaccines have been tested in combination with other therapeutic approaches, including check point inhibitors.
Conclusions:
It seems possible that the efficacy of sipuleucel-T and PROSTVAC could be increased in combination therapy with other medications.
Insights
Therapeutic cancer vaccines show promise for prostate cancer treatment. Sipuleucel-T and PROSTVAC are leading options, with potential for enhanced efficacy when combined with other therapies.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Therapeutic cancer vaccines have been a focus in oncology for decades.
- Sipuleucel-T is the only FDA-approved cancer vaccine, targeting prostatic acid phosphatase.
- Limited success has been achieved despite extensive research efforts.
Purpose of the Study:
- To review advanced research on therapeutic cancer vaccines for prostate cancer.
- To compare the most promising vaccines, sipuleucel-T and PROSTVAC.
- To explore combination therapy strategies.
Main Methods:
- Literature review of advanced research on therapeutic cancer vaccines.
- Comparison of sipuleucel-T and PROSTVAC.
- Analysis of clinical trial data for prostate cancer vaccines.
Main Results:
- Sipuleucel-T (anti-PAP) approved in 2010.
- Four other vaccines (GVAX, PPV, PCVAC, PROSTVAC) tested in Phase III for metastatic castration-resistant prostate cancer (mCRPC).
- Sipuleucel-T and PROSTVAC are the most studied, currently evaluated in combination with checkpoint inhibitors.
Conclusions:
- Combination therapy may enhance the efficacy of sipuleucel-T and PROSTVAC.
- Further research into combination strategies is warranted.
- Cancer vaccines represent a developing area in prostate cancer treatment.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Microorganisms in Medicine and Therapeutics

